BS 006
Alternative Names: BS-006; oHSV2-BiTEs; oHSV2-PD-L1/CD3-BsAb; Recombinant oncolytic type II herpes simplex virus -Binhui BiopharmaceuticalLatest Information Update: 02 Jan 2024
At a glance
- Originator Binhui Biopharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Oncolytic viruses
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Intratumoural) (NCT05938296)
- 30 Jun 2023 Binhui Biopharmaceutical plans a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) (Intratumoral Injection) (NCT05938296)
- 20 Jun 2022 Preclinical trials in Solid tumours in China (Intratumoural) (Wuhan Binhui Biopharmaceutical pipeline, June 2022)